Literature DB >> 22346416

Antimicrobial treatment of community acquired pneumonia in adults: A conference report.

L Mandell, M Niederman.   

Abstract

Entities:  

Year:  1993        PMID： 22346416      PMCID： PMC3250812          DOI： 10.1155/1993/308589

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN： 1180-2332


× No keyword cloud information.
  8 in total

1.  Susceptibility of Haemophilus influenzae to antimicrobial agents used in Canada. Canadian Study Group.

Authors:  L D Tremblay; J L'Ecuyer; P Provencher; M G Bergeron
Journal:  CMAJ       Date:  1990-11-01       Impact factor: 8.262

2.  New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases.

Authors:  G D Fang; M Fine; J Orloff; D Arisumi; V L Yu; W Kapoor; J T Grayston; S P Wang; R Kohler; R R Muder
Journal:  Medicine (Baltimore)       Date:  1990-09       Impact factor: 1.889

3.  Hospitalizations for the leading causes of death among the elderly--United States, 1987.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1990-11-02       Impact factor: 17.586

4.  Severe community-acquired pneumonia. Etiology, prognosis, and treatment.

Authors:  J Pachon; M D Prados; F Capote; J A Cuello; J Garnacho; A Verano
Journal:  Am Rev Respir Dis       Date:  1990-08

5.  Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study.

Authors:  M J Fine; D N Smith; D E Singer
Journal:  Am J Med       Date:  1990-12       Impact factor: 4.965

6.  Severe community-acquired pneumonia. Epidemiology and prognostic factors.

Authors:  A Torres; J Serra-Batlles; A Ferrer; P Jiménez; R Celis; E Cobo; R Rodriguez-Roisin
Journal:  Am Rev Respir Dis       Date:  1991-08

7.  Predicting death in patients hospitalized for community-acquired pneumonia.

Authors:  B M Farr; A J Sloman; M J Fisch
Journal:  Ann Intern Med       Date:  1991-09-15       Impact factor: 25.391

8.  Community-acquired pneumonia requiring hospitalization: 5-year prospective study.

Authors:  T J Marrie; H Durant; L Yates
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug
  8 in total
  16 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Community-Acquired Pneumonia: An Overview.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  Reasons for choice of antibiotic for the empirical treatment of CAP by Canadian infectious disease physicians.

Authors:  J Pendergrast; T Marrie
Journal:  Can J Infect Dis       Date:  1999-09

Review 4.  Role of Marine Natural Products in the Genesis of Antiviral Agents.

Authors:  Vedanjali Gogineni; Raymond F Schinazi; Mark T Hamann
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

Review 5.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  How Nova Scotia general practitioners choose antibiotics for the empirical treatment of community-acquired pneumonia.

Authors:  J Pendergrast; T J Marrie
Journal:  Can J Infect Dis       Date:  2000-11

7.  Guidelinitis: A new syndrome?

Authors:  B L Johnston; J M Conly
Journal:  Can J Infect Dis       Date:  2000-11

8.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Can J Infect Dis       Date:  2000-09

Review 9.  Nursing home-acquired pneumonia. Treatment options.

Authors:  T J Marrie; K L Slayter
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 10.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.